Neuroblastoma is a neural crest-derived neoplasm of infancy with poor outcome in patients with advanced disease. The oncogenic transcription factor PAX5 is an important developmental regulator and is implicated in the pathogenesis of several malignancies. Screening of neuroblastoma cell lines revealed PAX5 expression in a malignant subset of neuroblastoma cells, so-called`N-type' cells, but not in the more benign`S-type' neuroblastoma cells. PAX5 expression was also detected in small cell lung cancer, an aggressive tumor of neural crest origin. Based on this observation we hypothesized that there could be a relationship between PAX5 expression and the more malignant phenotype of N-type cells. Stable PAX5 expression was established in several clones of the S-type cell line CA-2E. A noticeable difference in morphology of these transfectants was observed and there was also a significant increase in the proliferation rate. Moreover, PAX5 expressing clones gained the ability to form colonies in a soft agar assay, a marker of tumorigenicity. Down-regulation of PAX5 in several N-type cell lines and one small cell lung cancer cell line utilizing small interfering RNA resulted in a significant decrease in growth rate. Taken together we propose PAX5 as an important factor for the maintenance of the proliferative and tumorigenic phenotype of neuroblastoma. Our data, together with a recent study on the role of PAX genes in cancer suggest that PAX5 and other PAX transcription factors might be valuable targets for cancer therapy.
Introduction
Neuroblastoma is the most common extracranial solid tumor in children and is the leading cause of cancer death in children between 1 and 4 years (1, 2) . It is a neoplasm of the neural crest, a transient embryonic structure giving rise to a variety of tissues (e.g. melanocytes, neurons, neuroendocrine tissue and smooth muscle cells) (3) . Histologically neuroblastoma tumors are composed of distinct malignant cell types, including neuroblastic and stromal cells (1) .
Cellular diversity is also characteristic of cell lines established from explanted neuroblastoma tumors. A number of subpopulations have been identified in these cultures, including neuroblastic (N-type), substrate adherent (S-type) cells and cells with an intermediate phenotype (I-type). These cell types can be distinguished by a characteristic morphology (4EE6). Analysis of homogeneous cultures of these subtypes has shown that they can also be distinguished by the expression of a number of differentiation-associated markers. N-type cells express neurotransmitter biosynthetic enzymes, chromogranin A and neurofilament proteins while S-type cells synthesize collagen, fibronectin and vimentin (4, 7) . In contrast to S-type cells, N-type cells are tumorigenic in nude mice and form colonies in soft agar (8) . The difference in malignant properties between S-and N-type cell subtypes may have clinical relevance (9) . At the transcriptional level several differences in gene expression have been detected. For example, BCL2 and MYCN are usually expressed at a higher level in N-type cells (10, 11) . The difference in MYCN expression was observed in both MYCN amplified and non-amplified cell lines (11, 12) . Recently it has been demonstrated that S-type in contrast to N-type cells are more susceptible to TRAIL-mediated apoptosis due to their expression of caspase-8 (13, 14) .
PAX5 is a member of the PAX gene family of developmentally regulated transcription factors that play a fundamental role in organogenesis (15) . All PAX transcription factors share a DNA binding domainÐthe paired box. Their importance in development has been underscored by several loss-of-function mutations that cause lack of a specific structure or organ in which the corresponding PAX gene is normally expressed. Typically, PAX protein expression is down-regulated in the adult organism. During mouse brain development Pax5 is expressed predominantly at the midbrainEEhindbrain boundary. A weaker expression is found along the entire neural tube, particularly in the ventricular zone of both alar and basal plates (16) . A similar expression pattern has been described recently in human embryos (17) . In addition, Pax5 is expressed during all stages of B-cell development, except in plasma cells (18) .
Pax5
ÀaÀ mice lack mature B cells and show defects of the inferior colliculus and anterior cerebellum (19) .
In addition to the normal physiological function during development, PAX transcription factors have been shown to play an important role in tumorigenesis (reviewed in ref. 20) . First, a number of PAX genes are located at recurring, tumorspecific chromosomal translocations, suggesting that PAX genes have an oncogenic capacity when inappropriately expressed. Secondly, several PAX genes are re-expressed in malignant neoplasms, usually in tumors derived from tissue in which the respective PAX gene is expressed during development. For example, deregulated expression of PAX5 has been described in medulloblastoma and lymphomas (21, 22) and of PAX3 in melanoma (23) . It is speculated that the re-expressed PAX genes promote tumor development and progression by increasing proliferation and motility, while inhibiting apoptosis (20) .
Here we describe that PAX5 is expressed in aggressive N-type neuroblastoma cell lines, while no expression was detected in S-type cells. Over-expression of PAX5 in the S-type cell line CA-2E restored several malignant properties, in particular anchorage-independent growth. In addition downregulation of PAX5 in several N-type cell lines significantly reduced their proliferation rate. These results provide additional evidence for an important role of the PAX gene family in tumor development and suggest a role for PAX5 in neuroblastoma disease progression.
Materials and methods
Cell lines ACN, CA-2E, BE(2)C, BE(2)M17, Imr32, Kelly, LAN-1, LAN-5, SH-310, SH-EP, SH-IN, SK-N-BE(2), SH-SY5Y and WSN were kindly provided by Nicole Gross (University Hospital, Lausanne, Switzerland). U1285 was a kind gift of Larisa Belyanskaya (Universitaetsspital, Zurich, Switzerland), MMLI157 was provided by Juerg Zarn (formerly Universitaetsspital Zurich, Switzerland) and Kis-1 was kindly provided by Hitoshi Ohno (Kyoto University, Kyoto, Japan). SW2, OH1 and OH3 have been described previously (24) . A549, Calu1, Calu3, Calu6, H460, NCI-H69 and NCI-H125 were obtained from ATCC (Rockville, MD). All cell lines were cultured in RPMI1640 supplemented with 10% FCS, 2 mM L-glutamine, 50 IU/ml penicillin and 50 mg/ml streptomycin and maintained at 37 C in a humified atmosphere with 5% CO 2 .
RTEEPCR RNA was isolated from cell lines using the RNeasy Mini Kit according to the manufacturer's instructions (Qiagen, Basel, Switzerland). Five micrograms of total RNA were used to synthesize cDNA using the M-MuLV reverse transcriptase according to the manufacurer's instructions (MBI Fermentas, Vilnius, Lithuania). One-hundredth of the product was used for amplification using primers for PAX5 or GAPDH and PCR conditions as described elsewhere (25) .
Plasmid construction
A mammalian PAX5 cDNA expression plasmid designated pX-13 was generated by cloning a 3.3 kb XbaI fragment from phBSAP-1s (a kind gift of Meinrad Busslinger, Research Institute of Molecular Pathology, Vienna, Austria) into the mammalian expression vector pcDNA3.1/Hygro() (Invitrogen, Basel, Switzerland) using standard methods (26) . This fragment contained the fulllength PAX5 coding sequence (1176 bp) together with 77 bp of the 5 H -UTR and 2026 bp of the 3 H -UTR sequence. The correct orientation of the PAX5-cDNA was confirmed by sequencing (Microsynth, Balgach, Switzerland).
Cell transfection and generation of stable cell lines Transfection of the plasmids was performed with Superfect following the manufacturer's instructions (Qiagen, Basel, Switzerland). Stable clones were generated by transfecting CA-2E cells with plasmids pX-13 or pcDNA3.1/ Hygro() for 20 h. The transfection medium was aspirated and cells were cultured in fresh medium for another day before adding 400 mg/ml hygromycin B for selection. Single clones were achieved by plating the cells in 96-well plates after 7EE10 days of selection at a density of 0.5 cells/well in 100 ml selective medium. Single clones were expanded and screened for PAX5 expression by immunoblotting.
Cell lysis and immunoblotting
Cells were harvested and pellets were frozen at À80 C for at least 1 h. RIPA buffer was used for cell lysis as described (22) . Between 80 and 120 mg of total lysate was separated by SDSEEPAGE on a 10% gel. Transfer and immunoblotting conditions have been described previously (24) . For PAX5 and actin detection the Pax5-C14 antibody (Santa Cruz Biotechnology, Santa Cruz, CA) or an anti-Actin antibody (ICN Biomedicals GmbH, Eschwege, Germany) have been used respectively and were combined with the corresponding secondary antibodies. Chemoluminescent signals were detected using the ECL Kit (Amersham Biosciences, Buckinghamshire, UK). Band intensities were measured using standard methods.
Growth experiments 5000 cells were plated in 6-well plates containing 3 ml RPMI 1640 supplemented with 5% FCS, 2 mM L-glutamine, 50 IU/ml penicillin and 50 mg/ml streptomycin. Cells were grown at standard conditions and harvested after 4 days. After centrifugation the cells were re-suspended in PBS and the number of cells was determined using a Coulter counter (Beckman Coulter, Fullerton, CA). The harvesting and counting procedure was repeated every 24 h for an additional 5 days. Experiments were performed in triplicate and repeated four times with similar results.
Soft agar assay
To determine the ability of anchorage-independent growth a soft agar clonogenic assay was performed with PAX5 positive and negative clones. A base solution consisting of 1.5 ml 0.5% agar in culture medium was poured in each well of a 6-well plate. 3000 cells were re-suspended in 1.5 ml top solution consisting of 0.35% agar in culture medium and subsequently seeded on top of the polymerized base solution. All solutions were kept at 40 C before pouring to prevent early agar polymerization and to ensure survival of the cells. Plates were incubated at 37 C under standard culture conditions for 28EE32 days and colony formation was visualized by staining with 0.01% crystal violet and quantified by counting. All experiments were performed in triplicate and experiments were repeated five times with similar results.
Xenografts
Six to eight week old female CD-1 (ICR nu/nu) mice (Charles River Laboratories, Sulzberg, Germany) were used and kept under specific pathogenfree conditions according to the guidelines of the Veterinary Office of the Kanton Zurich, Switzerland. Ten million cells re-suspended in sterile PBS were injected subcutaneously on the flanks. Tumor growth was assessed by measuring tumor size once per week.
Immunohistochemistry
Formalin-fixed and paraffin-embedded tumor samples were subjected to immunohistochemical staining for PAX5 and Vimentin as described elsewhere (27) . The primary anti-Pax-5 (Transduction Laboratories, Lexington, KY) and anti-Vimentin (DAKO, Glostrup, Denmark) were used.
Transfection with small interfering RNA (siRNA) and measurement of cell proliferation Briefly, for each experiment 5 Â 10 5 cells/well were plated in 6-well plates and transfected with 80 nM siRNA or scrambled control RNA (scRNA) for 24 h using Lipofectamine 2000 as a transfection mediator according to the manufacturer's instructions (Invitrogen, Basel, Switzerland). The sequences of the sense strand and of the complementary strand of the siRNA and scRNA were as follows: siRNA sense strand 5 H -CGGCCACUCGCUUCCGGGCTT-3 H , complementary strand 5 H -GCCCGGAAGCGAGUGGCCGTT-3 H and scRNA sense strand 5 H -GCUCCGUCGACUGCGCGCC-3 H , complementary strand 5 H -GGCGCGCAGUCGACGGAGCTT-3 H . These compounds were ordered as double-stranded RNA with a 2-nt DNA overhang (i.e. TT) at both 3 H -ends (Proligo, Paris, France).
Cell proliferation was measured by use of a colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay as described previously (28) . Twenty-four hours after treatment with siRNA or scRNA, cells were plated in 96-well plates and incubated in standard culture medium containing only 5% FCS under standard conditions. The amount of plated cells per well was as follows: LAN-1 and OH1 (1.5 Â 10 4 ), Imr32 and MMLI157 (2 Â 10 4 ). The first MTT assay was performed immediately after distributing the cells in order to confirm the accuracy of the plating. Cell proliferation was assessed 24, 48, 72 and 96 h after plating. Data recording and analysis was performed as described previously (28) . An individual standard calibration curve was constructed for each cell line and absorption values were equalized with the cell number by use of these standard curves.
Results
Expression of PAX5 in N-type neuroblastoma and small cell lung cancer cell lines Based on the observation that deregulated expression of PAX genes is often observed in tumors derived from tissues in which the respective PAX gene is expressed during normal organogenesis, we screened tumors of the nervous system for PAX5 expression by RTEEPCR. Expression of PAX5 mRNA was detected in seven N-type and parental neuroblastoma cell lines while no transcripts were present in all four S-type neuroblastoma cell lines and in two out of three I-type cell lines ( Figure 1A) . In order to compare the relative abundance of the two PAX5 isoforms, which differ only in the first exon (29) , we performed a quantitative Real-Time PCR with primers specific for isoforms 1A and 1B. All neuroblastoma cell lines that were positive for PAX5 in the conventional RTEEPCR expressed isoform 1B. It was only in a few cases that a very low expression of the 1A isoform could be detected as well (unpublished data). These findings are consistent with data showing that the 1B promoter is predominantly used for PAX5 expression in non-B lymphocytes (30) . PAX5 expression in N-type and absence in S-type cells could be confirmed at the protein level by immunoblotting. A major band of the expected size of~50 kDa was detected in lysates prepared from N-type cell lines and the B-cell line Kis-1, but not in S-type cells. The minor bands above the band representing PAX5 are non-specific and also visible in S-type cells. An actin control is included to ensure equal loading ( Figure 1B) .
As neuroblastoma is a neural crest-derived tumor, we also screened additional tumors of the neural crest for PAX5 mRNA expression. While no expression could be detected in five melanoma cell lines (unpublished data), expression of PAX5 was found in five small cell lung cancer (SCLC) cell lines but not in five non-small cell lung cancer (NSCLC) cell lines, which are of endodermal origin ( Figure 1C) .
In summary, PAX5 expression was detected at the mRNA and protein level in N-type neuroblastoma and SCLC cell lines but not in any of the S-type neuroblastoma, melanoma and non-neural crest-derived NSCLC cell lines, suggesting a role for PAX5 in the more aggressive phenotype of these cell lines.
Stable expression of PAX5 in S-type neuroblastoma cell line CA-2E To investigate the possibility that the differential expression of PAX5 in N-but not S-type neuroblastoma cell lines could in part account for their distinctive phenotypes, we generated several independent clones of the S-type neuroblastoma cell line CA-2E with stable expression of PAX5. To this end we used the PAX5-cDNA expression vector pX-13 and the empty cloning vector pcDNA3.1/Hygro() as a control. A number of clones transfected with either vector pX-13 or the control vector were isolated after transfection and limiting dilution. Chromosomal integration of the PAX5 expression vector or the empty cloning vector was confirmed by vector-specific primers. PAX5 expression in these clones was determined by immunoblotting ( Figure 2A ). Three PAX5 expressing clones (P-16, P-25 and P-28) and three clones transfected with the empty vector (C-43, C-45 and C-50) were randomly selected for further phenotypic analysis. The use of a control vector transfected in parallel and the analysis of three independent clones of each transfected vector should eliminate the possibility of selecting pre-existing clones. To exclude this possibility using an additional method, we performed fluorescence in situ hybridization (FISH) experiments with a MYCN probe (Vysis, Downers Grove, IL). This experiment showed the presence of two major populations with either three or four MYCN copies per cell in the untransfected CA-2E cell line. There was no significant difference in the number of cells with three or four copies between the P and C clones, thereby excluding selection of a subclone with a particular MYCN copy number (unpublished data).
PAX5 expression in CA-2E neuroblastoma cells changes cell morphology and increases growth rate Direct microscopy of cell cultures of PAX5 expressing CA-2E cells revealed distinct morphologic differences compared with control cells. The latter consisted of flat, epithelial-like cells with a large cytoplasm with no significant difference to untransfected CA-2E cells ( Figure 2B ). In contrast, PAX5 expressing cells became smaller, rounder and were less attached to plastic which was closer in morphology to N-type cells ( Figure 2C ). The observed cell rounding was not due to apoptosis as shown by propidium iodine staining followed by FACS analysis (unpublished data).
Growth kinetics were analyzed by seeding 5000 cells of each of two positive and negative PAX5 clones and counting cell numbers after different time points. Compared with PAX5 negative clones, the positive clones grew significantly faster 
PAX5 in neuroblastoma
and to a higher cell number before the growth curves reached their plateau (Figure 3) . Moreover, there was no difference in growth kinetics between the CA-2E cell line and the control vector transfected cell line (unpublished data).
PAX5 expression greatly increases anchorage-independent growth of CA-2E cells Previous studies have shown that S-type cells isolated from mixed neuroblastoma cell populations are less tumorigenic than N-type cells, based on their differential ability for colony formation in soft agar assays or tumor formation in nude mice (8) . Consistent with these observations CA-2E cells formed nearly no colonies in our soft agar system, in contrast to the N-type cell lines SH-SY5Y and LAN-1 (unpublished data). PAX5 expressing CA-2E clones formed a large number of colonies that were nevertheless smaller in size compared with colonies formed by the N-type cell lines SH-SY5Y and LAN-1. The control clones were comparable with the wildtype CA-2E cells with almost no colony formation (Figure 4 ). These observations could be reproduced for all clones in several different experiments. Taken together these results indicate that PAX5 expression can increase anchorageindependent colony formation when over-expressed in the appropriate cellular background.
PAX5 expression promotes tumor formation in nude mice
In in vivo experiments the PAX5 expressing P-25 and the nonexpressing C-43 cells were injected into four CD-1 nude mice each on the lateral flank. Two mice injected with P-25 developed small tumors with a size of 130 and 230 mm 3 after 4 months whereas mice injected with C-43 did not form any tumors. To confirm this result in a larger population we injected P-25 cells into seven mice. Although we injected the cells in both flanks only two mice developed tumors with a size of 85 mm 3 . Immunohistochemical analysis of the tumors from both experiments confirmed that they were derived from P-25 as they expressed PAX5 as well as the CA-2E marker Vimentin (Figure 5A and B) . Immunoreactivity for PAX5 was present in the nucleus and co-localized with Vimentin staining in the same cells.
PAX5 down-regulation with siRNA decreases cell proliferation of N-type neuroblastoma cells As shown in our growth experiments, stable PAX5 expression significantly increased the growth rate of CA-2E cells. As N-type cells already express endogenous PAX5 we exploited the RNA interference (RNAi) technique (31) in order to specifically down-regulate PAX5 mRNA. We designed an siRNA against PAX5 mRNA and an scRNA consisting of the same bases organized in a randomized combination without any homology to human genomic sequences. The N-type neuroblastoma cell lines LAN-1 and Imr32 as well as the SCLC cell line OH1 were either transfected with siRNA or the same amount of scRNA. The melanoma cell line MMLI157, which does not express endogenous PAX5 was used as a control. Immunoblot analysis of cells transfected with siRNA and harvested 72 h after transfection showed a down-regulation of the PAX5 protein level by 32% in LAN-1 cells and by 12% in Imr32 and OH1 cells when compared with scRNA treatment ( Figure 6AEEC ). Staining for actin was used as a loading control and is also shown.
Proliferation of transfected cells was measured by a MTT assay. A modest but significant decrease in growth of the siRNA transfected cells compared with scRNA transfected cells was first observed 48 h after plating ( Figure 6AEEC ). The effect was greatest in LAN-1 where the PAX5 downregulation worked most effective and small in OH1 where PAC5 was weakly down-regulated. In addition the control cell line MMLI157 was unaffected by either treatment ( Figure  6D ).
Discussion
In this study we report the expression of the oncogenic transcription factor PAX5 in a subset of neuroblastoma cell lines characterized by an aggressive phenotype, the so-called`N -type' cells. In contrast, PAX5 was not expressed in any of the tested S-type neuroblastoma cell lines. Further screening of neural crest-derived tumors demonstrated expression in SCLC but not in melanoma cell lines. The data show a distinct expression pattern of PAX5 in neural crest-derived tumors with a neuronal or neuroendocrine differentiation, indicating that PAX5 might be a valuable marker for these derivatives. The lack of expression in both melanoma cell lines and S-type cell lines is consistent with the model of S-type cells being differentiated along the melanocyte pathway (4).
More significantly, the expression of PAX5 in N-type neuroblastoma cells might be an important determinant of the more malignant phenotype of these cells. To test this hypothesis two approaches were taken. First, PAX5 was over-expressed in the S-type neuroblastoma cell line CA-2E, resulting in a remarkable phenotypic change. Secondly, PAX5 was down-regulated in N-type cell lines and SCLC cell line by means of the siRNA technique. A recent report has shown the coexistence of subpopulations with different MYCN copy numbers in the neuroblastoma cell line SK-N-SH and the derived cell lines SH-SY5Y (N-type) and SH-EP (S-type). It was suggested that the phenomenon of phenotypic interconversion is likely to result from selection of pre-existing clones that can outgrow 
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under certain conditions (32) . The selection of a subclone with a higher MYCN copy number could therefore account for the increase in aggressiveness seen in our clones transfected with PAX5. To exclude this important possibility we performed FISH analysis with the MYCN probe in the untransfected CA-2E cell line and the transfected clones. We could indeed detect the coexistence of two populations with respect to MYCN copy number, but no evidence of selection after transfection. Therefore, these results provide evidence that the phenotypic changes observed by us, including the increase of tumorigenicity, are a result of the expression of PAX5 in CA-2E cells.
The cellular background of the CA-2E cell line proved to be particularly permissive to mediate the effects of PAX5 expression, most likely because interacting co-factors required for PAX5 function are present. CA-2E was established from the bone marrow aspirate of a 16-month-old patient with progressive disease (33) . The cells have the typical morphology of S-type cells and do not form colonies in a soft agar assay. PAX5 expression resulted in a striking increase in colony numbers. The size of the individual colonies, however, was smaller than those formed by the N-type cell line SH-SY5Y. Consistent with this observation, PAX5 expressing cells formed tumors only with low efficiency in animals. These results are reminiscent of observations made when analysing the transforming capacity of the PAX3EEFKHR fusion protein (34) . Expression of this fusion protein in chicken embryo fibroblasts led to cellular transformation in vitro, as shown in focus and soft agar colony assays. In animal experiments, however, no in vivo transforming capacity could be demonstrated. It is possible that tumor induction in vivo requires additional genetic changes or induction of additional genes (e.g. responsible for neo-angiogenesis) that are not required for colony formation in soft agar. In addition, several other attempts to induce tumors in transgenic models by overexpressing PAX5 or PAX3-FKHR have failed (35EE37). These Fig. 6 . Down-regulation of PAX5 expression in N-type neuroblastoma and SCLC cell lines leads to a reduced growth rate. Endogenous PAX5 expression in the N-type neuroblastoma cell lines LAN-1 (A) and Imr32 (B) as well as in the SCLC cell line OH1 (C) was targeted by transfection of 80 nM of a sequence specific siRNA or 80 nM of a scrambled control scRNA. PAX5 protein level was determined 72 h after transfection by an immunoblot using 100 mg from total lysates (AEEC). Loading of equal amounts was verified by immunoblotting for actin. The proliferation of transfected cells was assessed using the MTT colorimetric assay at indicated time points (AEEC). MMLI157 was thereby used as a negative control (D). The number of cells was calculated according to a calibration curve to correlate optical density and cell number. An individual standard curve was constructed for each cell line. The data represent mean values and standard deviations of an experiment carried out in quintuplicate. results could indicate that deregulated expression of PAX genes is insufficient to cause tumor formation in vivo. However, these results do not exclude an important role for PAX gene expression in tumor progression or maintenance. Our observation that targeting of PAX5 expression in N-type neuroblastoma cell lines decreases proliferation supports this hypothesis.
Our results confirm other observations implicating mouse Pax5 as a positive regulator of cell proliferation (38) . In addition down-regulation of PAX5 in N-type cells affected growth, and we are currently trying to identify the target genes mediating this effect. A novel finding is our observation that PAX5 expression had a strong effect on S-type cell morphology and adhesion. This suggests that PAX5 might also regulate expression of cytoskeletal components and/or proteins of extracellular matrix.
Our study is limited by the fact that the effect of PAX5 overexpression was studied in only one S-type cell line. Nevertheless, the expression data and the effects of PAX5 expression in the S-type neuroblastoma cell line CA-2E suggest a role for PAX5 in the molecular pathogenesis of neuroblastoma tumors. Whether PAX5 might serve as a molecular target for therapy is not known. To investigate this possibility we have started an analysis of PAX5 expression in tumor samples. Recent findings of widespread expression of PAX genes in numerous common tumors and dependence of tumor viability on that expression suggest that PAX5 and other PAX transcription factors might be valuable targets for cancer therapy (39) . It is clear however, that the PAX5 transfected CA-2E cell line is a very useful model system to study the oncogenic function of PAX5. For example, the target genes mediating the oncogenic effect of PAX5 can be identified using microarray technology. Using this technique we have already identified several target genes that are regulated by PAX5 also in cell lines other than neuroblastoma cells (manuscript in preparation). The results of these studies will provide answers on how PAX5 performs its oncogenic function.
